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Digital gangrene was observed in a patient who had angiographic findings of digital 
arterial occlusion. The patient's blood showed a marked red blood cell aggregation with 
rouleaux formation in long chains, which could not be dispersed at shear rates up to 200 
sec -1. Studies of the patient's blood revealed the presence of an abnormal fibrinogen 
capable of aggregating normal red blood cells. This fibrinogen was found by Raman 
spectroscopy to have an increased a-helical content, whereas the g-sheet content was 
decreased. Defibrinogenation therapy with ancrod resulted in a dramatic symptomatic 
relief. The disappearance of the abnormal fibrinogen 6 months later and an absence of a 
family history indicate that this dysfibrinogenemia w s acquired. (J Vase Surg 1997; 
26:1061-8.) 
Microvascular occlusion by red blood cell (RBC) 
aggregation has been reported in several conditions, 
including diabetic retinopathy, 1-4 leg vein thrombo- 
sis, s chronic venous insufficiency, 6 retinal vein occlu- 
sion, 7,8 and macroglobulinemia. 9 The aggregates 
take the form of rouleaux, which may be sufficiently 
large to occlude small vessels. The causative factor for 
the aggregation depends on the specific disease en- 
tity. In the case of macroglobulinemia, high levels of 
the abnormal immunoglobulin M are believed to be 
the cause, whereas in diabetes, multiple factors are 
believed to be responsible, including severity of  dia- 
betes and the levels of plasma fibrinogen and serum 
%-globulin. In this article, we report digital ischemia 
complicated by gangrene in a patient with an unusual 
finding of marked RBC aggregation and rouleaux 
formation. An abnormal fibrinogen in the patient's 
plasma was found to be the cause of  the abnormal 
aggregation. 
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CASE REPORT 
The patient was a 56-year-old white man who had a 
sudden onset of cyanosis and pain in a finger. This spread 
to involve all his fingers and toes over the next 2 days. 
Otherwise, the patient had been in good health. There was 
no history of diabetes, Raynaud's phenomenon, cold intol- 
erance, or claudication, nor was there a history of cold 
exposure of his extremities. He was a moderate drinker 
(one to two beers a day) and a smoker (20 cigarettes per 
day), but had stopped smoking at the onset of his illness. 
There was no family history of thromboembolic diseases. 
Physical examination revealed cyanosis (Fig. 1) ofthe distal 
digits of his fingers, which were tender. Two fingers of his 
left hand showed gangrenous changes. His toes showed 
similar cyanosis but were not as tender. A bilateral arterio- 
graph of his upper limbs revealed normal filling of the 
proximal arteries and minor irregularity of the left radial 
artery in the forearm, absence of filling of the distal left 
radial and ulnar arteries, and decreased filling of both 
palmer arches. All digital rteries were poorly visualized 
beyond the level of the first interphalangeal joints (Fig. 2). 
Skin biopsy did not show evidence of vasculitis. He was 
treated with heparin, warfarin, prednisone, and vasodila- 
tors but did not obtain any relief. Over the following 3 
weeks, the gangrene of the two fingers of his left hand 
progressed and required amputation. Histopathologic ex- 
amination of the amputated material revealed that the deep 
dermal arteries showed microthrombi of varying ages. 
There were no cellular infiltrates in the arterial wall, thus 
excluding the diagnosis of Buerger's disease. Also, the 
absence of atrophy of the epidermis with preservation of
the dermal adnexal glands and periadnexal fat ruled out the 
diagnosis of scleroderma. 
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Fig. 1. Ischemic hanges in patient's digits are shown, with gangrene of two fingers in his left 
hand. 
The patient was then referred to us for further manage- 
ment. We made additional studies, including the findings 
of normal liver function tests and a normal-appearing 
echocardiogram. The patient's hemoglobin level, hemato- 
crit level, and cell counts of RBCs, white blood cells, and 
platelets were all normal, but microscopic examination of 
his peripheral blood smears revealed an impressive degree 
of RBC aggregation i the form of long rouleaux chains 
(Fig. 3). These were best shown in cover-slip reparations. 
Coagulation studies showed normal prothrombin time, 
normal activated partial thromboplastin time, a fibrinogen 
level of 342 mg/dl ,  and a normal euglobulin lysis time. His 
fasting blood glucose and serum immunoelectrophoresis 
results were normal. Further studies of cover-slip repara- 
tions of the patient's blood showed that the RBC aggre- 
gates could not be dispersed by increasing shear rates ofthe 
RBCs up to 200 sec -1. A direct antiglobulin (Coomb's) 
test had a negative result. 
A series of tests of this patient's blood were then 
performed. Mixtures of group O RBCs and test material 
(2:3 v/v to produce a packed cell volume of 40%) were 
observed microscopically for RBC aggregation i  cover- 
slip preparations after 10 minutes' incubation at 37 ° C. 
The results, shown in Table I, revealed that the patient's 
plasma was able to produce similar RBC aggregation with 
washed group O RBCs, whereas his serum was unable to 
do so. Because one major difference be tyeeen the plasma 
and the serum is the absence of fibrinogen in the latter, our 
findings strongly suggested that his fibrinogen might be 
responsible for this action. His plasma, after in vitro deft- 
brination by the addition of 1 unit of ancrod to 1.0 ml of 
plasma, was also unable to produce RBC aggregation, thus 
confirming the responsible role of the patient's fibrinogen. 
Because the RBC aggregation may also be dependent on 
the concentration f fibrinogen, the patient's plasma level 
of fibrinogen, initially checked by the thrombin clotting 
method of Clauss, 1° was also additionally assayed by the 
gravimetric method 1~ and immunodiffusion. 12 Results of 
all three methods were similar. 
Preparation of fibrinogen from his plasma was then 
made by barium chloride adsorption , and dialysis, followed 
by precipitation with 2.1 mol /L  glycine after the method 
of Kazal.la The fibrinogen preparation was 90% clottable. 
At a final concentration of 100 mg% or higher, this prepa- 
ration was also able to produce aggregation of washed 
group O RBCs. 
Because vibrational spectroscopy gives information re- 
garding the three-dimensional structure of molecules, we 
performed Raman spectroscopy on the purified fibrinogen 
preparation of our patient o examine the secondary struc- 
ture more closely. Samples were placed in Kimax capillary 
tubes of 2 mm diameter. The temperature was controlled 
by placing the tube (2.5 inches long) along a copper 
circulating tube (0.25 inch in diameter). Scattering at 180 
degrees was focused to a Spex 1401 double monochroma- 
tor, an RCA C31034 Ga-As photomultiplier, and modified 
Spex counting electronics. A Nova 2 /10 minicomputer 
controlled the scanning rate (1-S gate, 1 cm ~ step) and 
signal averaged (typically four spectra/average). The laser 
(At +, Spectra Physics 164) was excited at 488 nm and 
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Fig. 2. Arteriogram of patient's upper limbs shows bilaterally poor filling of palmar arch and 
absence of blood flow beyond the level of the first interphalangeal joints (A, left hand; B, left 
elbow; C, left shoulder; D, right hand; E, right elbow; F, right shoulder). 
delivered at least 250 mW at the sample. The incident laser 
radiation to the fibrinogen preparations was dispersed over 
a wide surface area on the capillary tubes to prevent heat- 
ing. Spectral resolution was approximately 3 cm -1 for slit 
widths of150 ixm. Intensities were accurate to within 0.15 
as determined from peak height intensity ratios. 
The results howed differences in various relative peak 
heights for the patient's fibrinogen as compared with nor- 
mal (Fig. 4). Representative Raman spectra of fibrinogen 
from the patient's fibrinogen and of normal fibrinogen are 
shown in Fig. 4. Moving from left to right, the 1450 to 
1300 cm -~ and 1150 to 1000 cm -I frequency regions have 
increased Raman intensity in the normal compared with 
the patient's fibrinogen spectrum as a result of resonance- 
enhancement of the N-H bending mode at approximately 
1426 cm -1 and the C-C stretching mode at approximately 
1130 cm -1. However, the important regions containing 
the protein secondary structure modes at approximately 
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Fig. 3. Cover-slip preparation of patient's blood shows rouleaux formation in long chains. 
Tab le  I .  RBC aggregat ion with rouleaux 
format ion in various mixtures o f  material  
der ived f rom pat ient  
Mixture Rouleaux 
Patient's citrated whole blood + 
Group O red cells + normal plasma 0 
Group O red cells + patient's plasma + 
Group O red cells + normal serum 0 
Group O red cells + patient's serum 0 
Group O red cells + patient's plasma 0 
defibrinated by ancrod 
Group O red cells + normal fibrinogen (final 0 
concentration 240 mg/dl) 
Group O red cells + patient's fibrinogen (final + 
concentration 240 mg/dl) 
Patient's citrated blood during ancrod treatment +* 
(fibrinogen 40 rag/all)* 
Observed at shear rates of 200 sec -1. Complex nondissociable 
rouleanx aggregates are reported as +, and when complex aggre- 
gates were not seen, it is reported as 0. 
*Instead of rotfleaux formation with long chains of red cells 
composed of 30 to 50 RBCs in each chain (Fig. 3), the aggregates 
are composed of only short chains of rouleaux of 3 to 4 red cells in 
each aggregate. 
1240 cm -t and 1000 to 750 cm -1, and in particular, the 
mode at 940 cm-1, are not influenced by this resonance 
enhancement. With normal fibrinogen, the peak at approx- 
imately 1240 cm -1 is narrow and well defined, indicating 
predominant random coil structure. In contrast, this band 
in the patient's fibrinogen spectrum is broad, flatter, and 
shifted to higher frequencies, reflecting predominant alpha 
helical content. The entire 1000 to 750 cm -1 region of the 
patient's fibrinogen has narrow, well-defined peaks that 
indicate predominant c~-helix, whereas the normal fibrino- 
gen has broader, less-intense peaks in the 1000 to 750 
cm 1 region, suggesting less R-helical content. The peak at 
940 cm ~ of the patient's fibrinogen is split into two peaks, 
indicating the presence of two R-helical structures. The 
relative intensity of the 940 cm -~ band as a result of the 
protein C-C stretch and the 1004 cm 1 band as a result of 
tryptophan and phenylalanine ring modes 47 is increased for 
the patient's versus normal fibrinogen, whereas the relative 
intensity of the I240 cm -1 band as a result of the protein 
amide II I  motion (N-H in plane bending) and the 1450 
cm -1 band as a result of methylene bending modes 48 was 
found to decrease. These relative peak height ratios can be 
related to the amount of {x-helix and [3-sheet structures in 
the proteins. 
On the basis of these findings, the patient underwent a 
trial of defibrinogenating therapy with ancrod, which was 
administered at a dosage of 2 units/kg body weight by 
intravenous injection over 10 minutes every 12 hours. His 
plasma fibrinogen level dropped to less than 50 mg/d l  
after 6 hours and remained low throughout the following 2 
weeks. Pain relief was obtained within 6 hours, along with 
the return of color and temperature to the digits of both 
his upper and lower extremities. There were no bleeding 
complications. Because ancrod is a foreign protein and 
thus antigenic, the therapy was stopped after 2 weeks. A 
repeat angiogram was not obtained. The patient remained 
free of symptoms thereafter. 
During therapy, even when the plasma fibrinogen was 
less than 10 mg/d l ,  the RBC aggregation persisted, but to 
a much lesser degree. Before ancrod therapy rouleaux for- 
mation consisted of long chains of RBCs composed of 30 
to 50 RBCs in each chain (Fig. 3), whereas after ancrod 
therapy the aggregates are composed of only short chains 
ofrouleaux of three to four RBCs in each aggregate. It was 
then believed that the abnormal fibrinogen might have 
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Table I I .  Immunofluorescence with 
fluorescein-labeled antifibrinogen serum 
showing adsorption of patient fibrinogen 
on RBCs 
RBC 
Mixture Fluorescence 
Normal blood* 0 
Patient's blood + 
Patient's blood during treatment with + 
ancrod 
Group O red cells + patient's plasma, + 
before ancrod treatment 
Group O red cells + normal defibrinated + 
plasma + patient's fibrinogen'~ 
Group O red cells + normal defibrinated 0 
plasma + normal fibrinogen~f 
Group O red cells + patient's plasma, 0 
during ancrod treatment (fibrinogen 
40 mg/dl) 
*Absence of immunofluorescent staining w th normal blood 
served as a negative control. 
~Fibrinogen had been reconstituted in normal defibrinated plasma 
(final concentration, 240 mg/dl). 
been adsorbed on the cell surface of his RBCs and that 
these cells had normal survival rates. This impression was 
confirmed by immunofluorescent studies of his RBCs us- 
ing fluorescein-labeled antihuman fibrinogen antibody, 
which showed positive fluorescence even after washing the 
RBCs three times with normal saline solution (Table II). 
However, the RBC aggregation disappeared 2 months 
later. His symptoms did not reappear, nor did he manifest 
other ischemic events such as occlusive coronary or cere- 
bral artery disease on follow-up examinations over the next 
5 years. Because the RBC aggregation disappeared, repeat 
studies of the patient's fibrinogen were not carried out. 
D ISCUSSION 
Our patient had digital ischemia nd gangrene as 
a result of  intravascular thrombosis. Although some 
arterial changes were shown on the upper limb an- 
giogram, these changes were not of sufficient severity 
to cause the gangrene. The only other significant 
abnormality found in our studies was his dysfibrino- 
genemia. His abnormal fibrinogen most likely led to 
the RBC aggregation and rouleaux formation. The 
latter, under low shear stress, caused rheologic im- 
pairment o the blood flow through his smaller ves- 
sels, leading to digital ischemia. 
Normal rheologic properties of the blood depend 
on its viscosity, which in large part is affected by the 
deformability and aggregation of  the RBCs. At low 
shear rates, which occur during blood flow through 
smaller vessels, the viscosity increases as a result of  
RBC aggregation, deformation, and orientation of 
the cells? 4 Thus factors that contribute to increased 
A 
o 
~,,,,,~CH2 and CH3 bend 
Trp, Phe ring modes 
.c f tAmide  III / retch (prot.) 
0 i u ~ u 
1800.0 1683.3 1366.7 1150.0 833.3 716.7 
Wavenumber (cm -1) 
Fig. 4. Representative Raman spectra of patient's fibrino- 
gen (A) and normal fibrinogen (B) in phosphate-buffered 
saline solution shows comparisons of respective tracings 
ranging from 716 to 1800 cm -1. 
RBC aggregation affect the viscosity and ultimately 
the blood flow. RBC aggregation occurs when the 
cell surface charge, the Z potential, is decreased by 
changes in the ambient fluid, such as increase in 
proteins, as in the case of macroglobulinemia and 
increased fibrinogen concentration, or by certain 
therapeutic agents such as high molecular weight 
dextran. 
A high fibrinogen level in the plasma is recog- 
nized to be a major and independent risk factor for 
coronary heart disease and for cerebrovascular dis- 
ease . i5 ,16  Current studies uggest that a high fibrino- 
gen level may affect blood coagulation, theologic 
characteristics, and platelet aggregability, ls 17,1s Al- 
though a high fibrinogen level is known to be associ- 
ated with increased RBC aggregation and increased 
blood viscosity, 19 our current finding is the first re- 
port of RBC rouleaux formation occurring at a nor- 
mal fibrinogen level. Although our patient did not 
have an elevated fibrinogen level, he had instead an 
abnormal fibrinogen that caused increased viscosity. 
The unusual RBC aggregation with marked rou- 
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Table I I I .  Diseases with reported increased 
RBC aggregation 
Caused by abnormalities in the plasma 
Diabetes t-4 
Leg vein thrombosis  
Chronic venous insufficiency 6 
Retinal vein occlusion 7,8 
Waldenstrom's macroglobulinaemia 9 
Hypercholesterolemia a2 
Primary hyperlipoproteinemia 33 
Preeclampsia a4 
Nephrotic syndrome as 
Hypertension a6 
Vancomycin a7
Occlusive cerebrovascular disease 3s
Unstable angina pectoris 39
Radiographic contrast media 4° 
Caused by abnormalities n the red cells 
~-thalassemia 4I 
Sickle cell traits 42 
Hereditary spherocytosis, elliptocytosis 43 
Babesia rgentina infection 44
Plasmodium knowlesi infection 4s
N~acetylneuraminic aciddeficienc)r~6 
leaux formation probably contributed to our pa- 
tient's digital ischemia. RBC aggregation increases 
the viscosity of blood at low shear rates. We believe 
that such an increased viscosity would enhance the 
flow stagnation and tendency to thrombosis. 
Our patient was treated with ancrod, which is 
derived from the venom of the Malayan pit viper 
(Agkistrodon rhodostoma). It releases fibrinopeptide 
A from the ~ chain of fibrinogen, resulting in the 
formation of fibrin with a different conformational 
change from that of thrombin-induced fibrin. This 
allows the ancrod-induced fibrin to be more suscep- 
tible to proteolysis by plasmin. 2°,2~ Thus, when used 
pharmacologically b  intravenous injection, ancrod is 
safe and will not produce a picture of disseminated 
intravascular coagulation. In our patient, ancrod ad- 
ministration resulted in a reduction of his plasma 
fibrinogen level to less than 50 mg/d l  and in prompt 
relief of his ischemic symptoms, with a return of 
color and temperature to his digits. We believe that 
the symptomatic relief was a result of  the decreased 
plasma fibrinogen level because the rouleaux forma- 
tion was concentration-dependent. This reduction in 
rouleaux would have resulted in a reduced blood 
viscosity. Because long-term use of Ancrod would 
lead to drug resistance from the production of anti- 
body against his foreign protein, we discontinued 
the ancrod treatment after 2 weeks. The absence of 
recurrence of the ischemic symptoms uggested that 
this condition of dysfibrinogenemia is selfqimiting. 
When reexamined 6 months later, there was no fur- 
ther rouleaux formation. An alternate method of 
treatment might be the use of low molecular weight 
dextran (Rheomacrodex). This agent is known to 
reduce blood viscosity. 22-24 
It is of interest that the degree ofrouleaux forma- 
tion is dependent on the concentration of the abnor- 
mal fibrinogen. After the therapeutic reduction of 
the plasma fibrinogen level by ancrod treatment, the 
patient's ymptoms dramatically abated even though 
the rouleaux were still present. The reduction in the 
size of the aggregates in this case was most likely 
sufficient o restore adequate flow to his ischemic 
tissues to produce symptomatic relief. 
The immunofluorescent studies indicated that 
the abnormal fibrinogen was bound to the RBCs, so 
that the increased RBC aggregation persisted even 
after the plasma fibrinogen level had fallen after an- 
crod defibrinogenation therapy. 
Increased RBC aggregation has been observed in 
many pathologic onditions. Those reported in the 
literature are listed in Table III. Abnormal fibrinogen 
is one of the more notable causes. A review of the 
literature of dysfibrinogenemia indicates that the ac- 
quired dysfibrinogenemia can occur in liver diseases, 
cancer, fibrinolysis, and disseminated intravascular 
coagulation.25 9These types of abnormal fibrinogen 
cause poor clot formation and bleeding diathesis. 
None were shown to predispose to thrombosis. In 
reviewing the congenital dysfibrinogenemias, we 
found that approximately 260 families have been 
afflicted. 3° When the records were analyzed by the 
Subcommittee on Fibrinogen of the International 
Society of Thrombosis and Hemostasis, sl 55% were 
asymptomatic, 25% had a bleeding tendency, and 
20% were associated with thrombosis. Various hy- 
potheses were put forth to explain those with throm- 
bosis. These include impaired lysis of the affected 
fibrin, increased fibrinogen binding to platelets, and 
an abnormal thrombin binding. No studies on rheo- 
logic changes were published. 
In our present patient, the disappearance of the 
rouleaux abnormality and the absence of a family 
history indicate that he had an acquired ysfibrino- 
genemia. The increased adsorption of the patients' 
fibrinogen to the RBC surface may reflect a structural 
abnormality of the fibrinogen molecule. This is sup- 
ported by the abnormal Raman spectroscopic pattern 
of the patient's fibrinogen. It is possible to assess 
relative changes in c~-helical and [3-sheet content of 
proteins by comparisons of the peak height intensity 
ratios 1940/I1004 and I1240/I1450. Specifically, an in- 
crease in the I940/I1004 intensity ratio would indicate 
an increase in the protein c~-helical content, 47 and a 
decrease in the I124o/I14s0 intensity ratio would in- 
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dicate a decrease in the content  o f  the prote in  [3- 
sheet  secondary structure.  4s The  compar i son  o f  these 
ratios f rom the spectra in Fig. 4 indicate that  the 
a-hel ica l  content  is increased, whereas the ]3-sheet 
content  is decreased in the compar i son  o f  the abnor-  
mal to normal  f ibr inogen.  The  change in abnormal  
f ibr inogen structure f rom ]3-sheet to a-hel ix  may 
result in the exposure o f  addit ional  membrane-b ind-  
ing sites on  the prote in ,  a l lowing for the RBC aggre-  
gat ion in microvasculature l ading to ischemia and 
digital  gangrenes.  O f  course,  the exact mechan ism 
relat ing increased f ibr inogen s -he l ica l  content  and 
increased RBC aggregat ion  is still unknown.  
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